GlaxoSmithKline trumpets a PhIII win in one of Hal Barron's handpicked drugs, a day after FibroGen's faceplant. Will it matter enough to critics?

Max Gelman

Senior Editor

As GlaxoSmithKline CEO Emma Walmsley charts a new course ahead of the Big Pharma’s planned split while simultaneously under immense pressure from activist investors, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GlaxoSmithKline trumpets a PhIII win in one of Hal Barron's handpicked drugs, a day after FibroGen's faceplant. Will it matter enough to critics?

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Minnesota 340B revenue driven by hospitals and high-priced drugs, first state report says

Glax­o­SmithK­line trum­pets a PhI­II win in one of Hal Bar­ron's hand­picked drugs, a day af­ter Fi­bro­Gen's face­plant. Will it mat­ter enough to crit­ics?

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Min­neso­ta 340B rev­enue dri­ven by hos­pi­tals and high-priced drugs, first state re­port says

GlaxoSmithKline trumpets a PhIII win in one of Hal Barron's handpicked drugs, a day after FibroGen's faceplant. Will it matter enough to critics?

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Minnesota 340B revenue driven by hospitals and high-priced drugs, first state report says